6/25/2013

Rebiotix has received fast-track designation from the FDA for its fecal transplant, which could speed up marketing approval for the product. The Roseville, Minn.-based biotech startup intends to use the product for patients with Clostridium difficile, a type of hospital-acquired bacterial infection.

Related Summaries